1. Genome Research Institute University of Cincinnati

2. Genome Research Institute Housed in facility donated by Aventis Pharmaceuticals ~360,000 sq. ft. of office, laboratory and vivarium space Currently houses 38 PIs, ~350 total researchers

3. GRI Capabilities Research Programs Molecular Mechanisms of Disease studies on the importance of aberrant pathway signaling in cancer and in metabolic diseases such as obesity and diabetes Obesity and Diabetes studies on the regulation of energy balance and glucose homeostasis in obesity and Type 2 diabetes studies on regulation of responses to environmental stressors with emphasis on behavioral and dietary interventions to optimize performance Lipid Metabolism elucidation of the roles of brain, intestine, and liver in regulation of plasma lipid metabolism, and the consequential effects on inflammation, cancer, atherosclerosis, obesity and development

4. Drug Discovery at GRI Biological Projects from academia, government, biotech and pharma Assays Proteomics Cell & Animal Models Cell & Animal Systems Genomics Toxicological Testing Phase 1 Clinicals Drug Development Bioinformatics Target Identification & Validation Phase High Throughput Screening, Medicinal Chemistry, Computation and Protein Phase Licensing, Co-Development, Pharma Partner Phase HTS Medicinal Chemistry Lead Compounds Validated Target Computer Modeling Protein Structure Protein Production Software Cell & Animal Models Diagnostics Drug Candidates Drug Candidates } Pharma-Quality 250,000 Compound Library GRI Capabilities

5. Drug Discovery at GRI Core Facilities Proteomics drug target identification & characterization drug candidate mechanism of action method development for posttranslational modification determination Protein Production production and purification of recombinant proteins (E. coli) Model Organisms use of Drosophila, zebrafish, and mouse to identify and validate potential drug targets Behavioral Studies characterization of rodent behavior in models of anxiety, learning and memory, motor function and locomotion, and drug side effects Mouse Metabolic Phenotyping Center (NIDDK) identification and validation of drug targets through characterization of lipid metabolism, cardiovascular & renal function, energy homeostasis, and behavior High-Throughput Screening rapid identification of structural leads for drug discovery programs

6. High-Throughput Screening Plate::explorer + Opera imaging system ultraHTS system Evotec-Technologies/Perkin-Elmer Up to 100,000 samples/24 hours

7. Applications Whole cell fluorescence assays Cell viability, cell differentiation, cell proliferation, cytotoxicity, apoptosis, transporter phenomena Cell signaling assays Calcium flux, second messengers, ion channels, membrane potential Gene expression assays Expression of house-keeping and reporter genes, gene activity and protein regulation, RNAi Membrane receptor assays Ligand binding, receptor activation and desensitization, translocation and endocytosis, recruitment of signaling molecules Translocation assays Target molecule redistribution Morphological assays Neurite outgrowth, cell differentiation, cell adhesion and spreading Opera Imaging Reader >50,000 multi-color data points/24 hours High-Throughput Screening

8. Compound Repository Haystack Neat Compound Storage Capacity = 200,000 bottles Current = 207,000 bottles Freezer storage when appropriate Solar (Solution Archive) – DMSO solutions Capacity = 1.8 million tubes, 10,000 deep well (96) plates, 13,600 shallow well (384) plates Current = 338,000 compounds in 383,400 tubes, 1862 deep wells and 2332 shallow wells Compound handling and dissolution instruments Housed at P&G’s Mason Business Center (~3500 sq. ft.)

9. GRI Compound Library It’s NOT just a numbers game – compound selection can greatly enhance screening efficiency Originally from P&G Pharma and represents a $22M investment Selected based on drug-like properties and to maximize structural diversity within a 6-dimensional “drug-like” space Both external (commercial suppliers) and internal discovery and combinatorial chemistry programs used as sources ~250,000 compounds Software to rapidly expand around structural leads identified Vendor Database Remove duplicates Remove reactives, Unusual groups, & toxicophores (80 substructures) MW filter Solubility Filter Lipinski Rule of Five > 5 H-bond donors MW < 500 c log P < 5  N's + O's < 10 “Cleaned” database 26 databases >4 million structures

10. Compounds Selected for Repository Defined by experienced medicinal chemists Broad, uniform distribution across Drug Space with concentrations of density in key areas from directed purchase and in house synthesis. Compare to 5 vendor screening collections 3,000 to 500,000 compounds 27% - 56% of vendors’ compound collections do NOT meet criteria for drug-like UC Compound collection is 2X to 100X more chemically diverse across Drug Space. Vendor Libraries are inherently predisposed to clustered groupings. We picked the best, most relevant compounds from each.

11. Molecular Modeling & Virtual Screening Protein – Ligand Docking Rapid docking algorithms for high volume virtual screening of drug targets against all commercially available compounds Detailed dynamic follow-up docking for enhanced accuracy and prediction of binding interactions. Pharmacophore Modeling Abstracting key pharmacophoric elements from molecular series, and using this as the basis for virtual screening. Nearest-Neighbor Analysis (hit expansion) Shape matched and general similarity based methods to identify compounds similar to leads.

12. Protein Docking Studies Small Molecule Modeling

13. Medicinal Chemistry Infrastructure 3300 sq. ft. of laboratory space available Synthesis Capability Flexibility built in to move between single compound and small library synthesis (for SAR determination) Compound Characterization Full Complement of Purification (Prep & analytical HPLC) and Analytical tools (NMR, LCMS)

14. Genome Research Institute What can we provide? Research expertise in signaling pathways, cancer, and metabolic regulation An academic drug discovery center with experienced leaders drawn from the pharma industry State of the art high-throughput and high-content screening capability Access to a highly-diverse library of drug-like compounds for screening Molecular modeling and in silico screening Behavioral and mouse phenotyping core facilities What are we looking for? Drug targets for screening Libraries of novel compounds Drug discovery collaborations Research collaborations in areas of interest Opportunities to create closer interactions with biotech and pharma companies

15. Further Information: Charles C. McOsker, PhD Director, Business Development & External Relations Genome Research Institute (513) 558-2569 (513) 885-2285 (cell) charles.mcosker@uc.edu